FDA Investigator Colleen F Hoyt
Colleen F Hoyt has inspections in 2 countries as of 09 Dec 2022. Colleen F Hoyt has collaborated with a combined 1354 experts on various inspections, contributing to compliance and improvement across diverse sectors.
Investigator Details
Number of Inspected Sites:
4
Last Inspection Date:
09 Dec 2022
Investigator Role:
FDA Investigator
Redica ID:
Country:
United States of America,
United Kingdom of Great Britain and Northern Ireland
Co-Investigator(s):
Alicia M Mozzachio,
Arlene M Badillo,
Ashley J Burns,
Brooke K Higgins,
Brooke K Seeman,
Carlos A Medina,
Carole L Jones,
CDR Ileana Barreto Pettit,
Charisse K Green,
Denis Gavin, PhD,
Diane T Bargo,
Diane T O'brien,
Dr. Carmelo Rosa,
Edwin Melendez,
Emest F Bizjak,
Erika V Butler,
Feiyan Jin,
Frederick L Fricke,
Ileana Pettit,
Jacqueline Mdiaz Albertini,
Joan Johnson,
Joe X Phillips,
Jonathan W Chapman,
Jorge L Lajara,
Jose A Moreno,
Jose E Melendez, DDC,
Jose R Lopez,
Kimberly L Schultz,
Laurissa S Flowers,
LCDR Anastasia Mpiliafas Brown,
Linda L Ng,
Lori S Lawless,
Marcellinus D Dordunoo,
Marianela Aponte Cruz,
Maribel V Juarbe,
Marie T Falcone,
Marta E Gonzalez,
Melissa J Garcia,
Merideth K Rose,
Michael E Maselli,
Michael R Goga,
Mra Davism,
Myriam M Sosa,
Nerizza B Guerin,
Patrice S Hall,
Patricia A Morrow,
Patrick L Wisor,
Rachel C Harrington,
Rafael Nevarez,
Rafael Nevarez Nieves,
Ramon A Hernandez,
Randa Melhem, PhD,
Rebecca Parrilla,
Rebecca Rodriguez,
Richard L Rutherford,
Russell J Glapion,
Sharmista Chatterjee,
Sharon K Thoma, PharmD,
Shirshendu K Deb, PhD,
Shusheen A Alexander,
Steven B Barber,
Steven D Kehoe,
Steven P Donald,
Susan M Jackson,
Suzanne M Healy,
Suzanne M Muchene,
Tajah L Blackburn,
Thai D Truong,
Thai Truong,
Unnee Ranjan,
Vipulchandr N Dholakia,
William J Leonard,
Xiaobin Lu (Victor), PhD,
Xiaohui Shen
Colleen F Hoyt's Documents
Publish Date | Document Type | Title |
---|---|---|
August, 2019 | FDA 483 Response | Novartis Pharmaceuticals Corporation - Form 483R, 2019-09-12 |
August, 2019 | EIR | Novartis Pharmaceuticals Corporation - EIR, 2019-08-21 |
October, 2007 | FDA 483 | Patheon Puerto Rico, Inc. - Form 483, 2007-10-29 |
August, 2019 | FDA 483 | Novartis Pharmaceuticals Corporation - Form 483, 2019-08-21 |
August, 2006 | FDA 483 | Bell-More Labs Inc - Form 483, 2006-08-17 |
October, 2018 | EIR | AGC Biologics, Inc. - EIR, 2019-11-13 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more